The FDA has approved GSK’s gepotidacin, the first antibiotic for uncomplicated urinary tract infections in 30 years.
The drug has been approved for female adults and adolescents with UTIs caused by common bacterial pathogens including E. coli and Klebsiella pneumoniae, according to a March 25 news release from the drugmaker.
The approval is based on two Phase 3 clinical trials which demonstrated that the drug was at least as effective as nitrofurantoin, a standard UTI treatment. The trials found that gepotidacin had a comparable safety profile, with mild to moderate gastrointestinal side effects being the most common.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
